Meeting Banner
Abstract #2208

Do gadolinium-based contrast agents alter 23Na T1 relaxivity in glioma?

Frank Riemer1, Mary A McLean2, Fulvio Zaccagna1, James T Grist1, Rolf F Schulte3, Joshua Kaggie1, Colin Watts4, Stephen J Price4, Martin J Graves1, and Ferdia A Gallagher1

1Department of Radiology, University of Cambridge, Cambridge, United Kingdom, 2Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, 3GE Global Research, Munich, Germany, 4Neurosurgery Division, Dept. of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

Incomplete fluid suppression on fluid-attenuated inversion-recovery 23Na-MRI (IR-23Na-MRI) was observed in three patients undergoing IR-23Na-MRI after gadolinium contrast injection, as part of a brain tumour imaging study. To evaluate this, 23Na-MRI T1 maps were acquired before and after injection of a gadolinium-based contrast agent on a grade IV glioma (GBM) patient, which showed a statistically significant change of 23Na-MRI T1 within the peritumoral oedema (p=0.0095). Gadolinium contrast-enhanced 23Na-MRI could potentially add further applications for sodium imaging and probe tumour tissue structure in new ways to investigate proliferation and treatment response.

This abstract and the presentation materials are available to members only; a login is required.

Join Here